{
  "abstract": "Background and Importance .Aim and Objectives To describe the pharmacist-led follow-up and optimisation of antiemetic therapy in colorectal cancer patients receiving moderately emetogenic chemotherapy, quantifying adjustments and their impact on symptom control.Material and Methods A prospective study was conducted between January and June 2024 in a regional hospital. Patients with colorectal cancer who received at least three cycles of moderately emetogenic chemotherapy were included.Follow-up was carried out in the Oncohaematology Pharmaceutical Care Clinic through structured clinical interviews after each cycle. Clinical and therapeutic information was obtained from the electronic medical record (Diraya) and the prescribing and validation system (Farmis-Oncofarm).All patients initially received the full NCCN-recommended regimen on day 1 of chemotherapy. From subsequent cycles, treatment was personalised, simplifying regimens and mainly using corticosteroids as maintenance, leading to less medication than international guidelines recommend.Efficacy was assessed as complete response (CR), defined as no vomiting and no rescue, and total control (TC), defined as absence of nausea, vomiting, and rescue.Results A total of 52 colorectal cancer patients were included, with a median age of 63.5 years (41–82); 59.6% were male and 3.8% had diabetes. The most frequent regimens were XELOX (28.8%), FOLFOX ± Bevacizumab (28.8%), FOLFIRI ± aflibercept/bevacizumab/cetuximab (30.8%), and Irinotecan ± Cetuximab (7.7%). At study closure, 67.3% were off antiemetic therapy.Regarding treatment adjustments, 88.5% (46) reduced the regimen, while 5.8% (3) required intensification with palonosetron/netupitant. Nausea occurred in 7.7% (4) and vomiting in 3.8% (2). Overall, CR was achieved in 94.2% (49) and TC in 92.3% (48). After intensification, all patients achieved CR and TC. Notably, no patient receiving XELOX required rescue antiemetics.Conclusion and Relevance Individualised antiemetic optimisation in colorectal cancer patients treated with moderately emetogenic chemotherapy enabled substantial regimen reduction while maintaining high rates of symptom control. Although all patients began with full NCCN protocols, later cycles were managed with simplified, corticosteroid-based approaches, resulting in markedly less medication without loss of efficacy. That all patients with reduction achieved CR and nearly all TC, while others required intensification to reach these outcomes, highlights the value of structured pharmacist-led follow-up. The excellent tolerability of XELOX, with no need for rescue therapy, suggests this subgroup could benefit from simplified initial antiemetic protocols.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitario De La Línea, Hospital Pharmacy, La Línea De La Concepción, Spain"
      ],
      "name": "A Trujillano"
    },
    {
      "affiliations": [
        "Hospital Universitario De La Línea, Hospital Pharmacy, La Línea De La Concepción, Spain"
      ],
      "name": "M Rodríguez Del Burgo"
    },
    {
      "affiliations": [
        "Hospital Universitario De La Línea, Medical Oncology, La Línea De La Concepción, Spain"
      ],
      "name": "FJ Valdivia García"
    },
    {
      "affiliations": [
        "Hospital Universitario De La Línea, Hospital Pharmacy, La Línea De La Concepción, Spain"
      ],
      "name": "M Gallego Galisteo"
    },
    {
      "affiliations": [
        "Hospital Universitario De La Línea, Hospital Pharmacy, La Línea De La Concepción, Spain"
      ],
      "name": "E Campos Dávila"
    }
  ],
  "title": "4CPS-045 Optimisation of antiemetic therapy based on individual response in colorectal cancer patients treated with moderately emetogenic chemotherapy",
  "uid": "7216aeac-75a6-57ba-af54-cf30719b88b1"
}